0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > VEGF-D

VEGF-D

Brief Information

Name:Vascular endothelial growth factor D
Target Synonym:C-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D),FIGF,c-Fos-induced growth factor,VEGFD,VEGF-D,Vascular Endothelial Growth Factor D
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
VED-H5228 Human Human VEGF-D Protein, His Tag
VED-H5228-structure
VED-H5228-sds
ACRO Quality

Part of Bioactivity data

VED-H5228-SPR
 VEGF-D SPR

Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 19.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

VED-H5228-BLI
 VEGF-D BLI

Loaded Biotinylated Human VEGF R3, His,Avitag (Cat. No. FL4-H82E1) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 110 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

FIGF,VEGFD

Background

Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Sozinibercept OPT-302; VGX-300 Phase 3 Clinical Orphan Europe Sarl Neovascularization, Pathologic; Retinal Diseases; Diabetic macular oedema; Retinal Degeneration; Eye Diseases; Macular Degeneration Details
EG-016 EG-016; Ad-VEGF-A Phase 2 Clinical Ark Therapeutics Ltd Peripheral Vascular Diseases Details
EG-011 EG-011; Ad-VEGF-D Phase 2 Clinical Ark Therapeutics Ltd Angina Pectoris Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken